Figures computed from official regulatory filings — .
Ownershipinsiders 19.69% · institutions 0%
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cell Source, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Soave Darlene | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brown Dennis M | Other | $2.2K | SEC |
| FRIEDMAN BENZION ABRAHAM | Other | $14.6K | SEC |
| ZOLTY DAVID | Other | $3.6K | SEC |
| Soave Darlene | Other | $44.6K | SEC |
| Brown Dennis M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FRIEDMAN BENZION ABRAHAM | Other | $4.1K | SEC |
| FRIEDMAN BENZION ABRAHAM | Other | $4K | SEC |
| SHIMRAT ITAMAR | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brown Dennis M | Other | $4.5K | SEC |
| FRIEDMAN BENZION ABRAHAM | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ZOLTY DAVID | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ZOLTY DAVID | Other | $1K | SEC |
| FRIEDMAN BENZION ABRAHAM | Other | $19.3K | Unusual size | SEC |
| Brown Dennis M | AwardD (derivative) | $50K | SEC |
| SHIMRAT ITAMAR | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FRIEDMAN BENZION ABRAHAM | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ZOLTY DAVID | Other | $4.8K | Unusual size | SEC |
| ZOLTY DAVID | AwardD (derivative) | $45K | SEC |
| ZOLTY DAVID | Other | $3.7K | SEC |
| ZOLTY DAVID | AwardD (derivative) | $59.2K | SEC |
| Brown Dennis M | Other | $2.2K | SEC |
| FRIEDMAN BENZION ABRAHAM | Other | $5K | SEC |
| FRIEDMAN BENZION ABRAHAM | Other | $14.7K | SEC |
| ZOLTY DAVID | Other | $1K | SEC |